This is the authors' abstract. We don't add key points for this paper.
Using Medicare claims, we documented US prescribing patterns for originator biologic trastuzumab (Herceptin), a targeted cancer therapy, and five biosimilar entrants since 2019. The first biosimilar captured a dominant share, but over time, average sales prices of all products declined, and later entrants became dominant in some states. Despite strong brand loyalty to the first biosimilar, competitive pressure increased with subsequent entrants.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: